Official Journal of the Human Genome Organisation
Table 6 Association between BRCA mutation carriers and breast cancer pathology
From: Clinical and pathological characteristics of Chinese patients with BRCA related breast cancer
BRCA mutations | ||||||||
|---|---|---|---|---|---|---|---|---|
Non-carriers (n = 198)* | Carriers (n = 28)* | Unadjusted | ||||||
n | Row % | n | Row % | χ2 | P-value | OR† | 95% CI | |
Age first diagnosed to have breast cancer | ||||||||
Age group: | ||||||||
≤40 | ||||||||
Without FH | 22 | 91.7 | 2 | 8.3 | 1.00** | |||
With FH | 52 | 78.8 | 14 | 21.2 | 2.00 | 0.22 | 2.96 | (0.62, 14.14) |
Without bilateral cancer | 63 | 85.1 | 11 | 14.9 | 1.00** | |||
With bilateral cancer | 11 | 68.8 | 5 | 31.2 | 2.42 | 0.15 | 2.60 | (0.76, 8.96) |
Non TN‡ | 46 | 83.6 | 9 | 16.4 | 1.00** | |||
TN‡ | 17 | 63.0 | 10 | 37.0 | 4.35 | 0.037 | 3.01 | (1.04, 8.67) |
41–45 | ||||||||
Without FH | 12 | 100.0 | 0 | 0.0 | 1.00** | |||
With FH | 38 | 92.7 | 3 | 7.3 | 0.93 | 1.00 | – | – |
Without bilateral cancer | 42 | 97.7 | 1 | 2.3 | 1.00** | |||
With bilateral cancer | 8 | 80.0 | 2 | 20.0 | 4.75 | 0.088 # | 10.50 | (0.85, 130.07) |
Non TN‡ | 33 | 97.1 | 1 | 2.9 | 1.00** | |||
TN‡ | 10 | 83.3 | 2 | 16.7 | 2.74 | 0.16 | 6.60 | (0.54, 80.61) |
46–50 | ||||||||
Without FH | 11 | 91.7 | 1 | 8.3 | 1.00** | |||
With FH | 27 | 87.1 | 4 | 12.9 | 0.18 | 1.00 | 1.63 | (0.16, 16.27) |
Without bilateral cancer | 29 | 90.6 | 3 | 9.4 | 1.00** | |||
With bilateral cancer | 9 | 81.8 | 2 | 18.2 | 0.62 | 0.59 | 2.15 | (0.31, 14.94) |
Non TN‡ | 23 | 85.2 | 4 | 14.8 | 1.00** | |||
TN‡ | 10 | 100.0 | 0 | 0.0 | 1.66 | 0.56 | – | – |
>50 | ||||||||
Without FH | 8 | 100.0 | 0 | 0.0 | 1.00** | |||
With FH | 27 | 90.0 | 3 | 10.0 | 0.87 | 1.00 | – | – |
Without bilateral cancer | 22 | 88.0 | 3 | 12.0 | 1.00** | |||
With bilateral cancer | 13 | 100.0 | 0 | 0.0 | 1.69 | 0.54 | – | – |
Non TN‡ | 29 | 96.7 | 1 | 3.3 | 1.00** | |||
TN‡ | 8 | 80.0 | 2 | 20.0 | 3.00 | 0.15 | 7.25 | (0.58, 90.55) |
Without bilateral cancer | ||||||||
Without FH | 44 | 95.7 | 2 | 4.3 | 1.00** | |||
With FH | 113 | 86.9 | 17 | 13.1 | 2.69 | 0.16 | 3.31 | (0.73, 14.92) |
With bilateral cancer | ||||||||
Without FH | 9 | 90.0 | 1 | 10.0 | 1.00** | |||
With FH | 32 | 80.0 | 8 | 20.0 | 0.54 | 0.67 | 2.25 | (0.25, 20.44) |
Non triple negative (ER−/PR−/Cerb2−)‡: | ||||||||
Without FH | 35 | 100.0 | 0 | 0.0 | 1.00** | |||
With FH | 96 | 86.5 | 15 | 13.5 | 5.27 | 0.022 | – | – |
Had triple negative (ER−/PR−/Cerb2−)‡: | ||||||||
Without FH | 16 | 88.9 | 2 | 11.1 | 1.00** | |||
With FH | 29 | 70.7 | 12 | 29.3 | 2.28 | 0.19 | 1.26 | (0.97, 1.62) |
No FH and non TN | 35 | 100.0 | 0 | 0.0 | ||||
No FH and TN | 16 | 88.9 | 2 | 11.1 | ||||
FH and non TN | 96 | 86.5 | 15 | 13.5 | ||||
FH and TN | 29 | 70.7 | 12 | 29.3 | 13.66 | 0.003 | – | – |
With family history | ||||||||
Non TN | 96 | 86.5 | 15 | 13.5 | 1.00** | |||
TN | 29 | 70.7 | 12 | 29.3 | 5.09 | 0.024 | 2.65 | (1.12, 6.29) |